Benefits of antiretroviral therapy initiation during acute HIV infection

References

• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
   Google Scholar
• Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822.
   Google Scholar
• Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization; 2015.
   Google Scholar
• Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PloS One. 2012;7(3):e33948.
   Google Scholar
• Robb ML, Ananworanich J. Lessons from acute HIV infection. Curr Opin HIV AIDS. 2016;11(6):555–560.
   Google Scholar
• Henn A, Flateau C, Gallien S. Primary HIV infection: clinical presentation, testing, and treatment. Curr Infect Dis Rep. 2017;19(10):37.
   Google Scholar
• McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10(1):11–23.
   Google Scholar
• Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871–1879. .
   Google Scholar
• Braun DL, Kouyos RD, Balmer B, et al. Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection. Clin Infect Dis. 2015;61(6):1013–1021.
   Google Scholar
• Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in east Africa and Thailand. N Engl J Med. 2016;374(22):2120–2130.
   Google Scholar
• Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125(4):257–264.
   Google Scholar
• Crowell TA, Colby DJ, Pinyakorn S, et al. Acute retroviral syndrome is associated with high viral burden, CD4 depletion, and immune activation in systemic and tissue compartments. Clin Infect Dis. 2018;66(10):1540–1549.
   Google Scholar
• Hoenigl M, Green N, Camacho M, et al. Signs or symptoms of acute HIV infection in a cohort undergoing community-based screening. Emerg Infect Dis. 2016;22(3):532–534.
   Google Scholar
• Braun DL, Kouyos R, Oberle C, et al. A novel acute retroviral syndrome severity score predicts the key surrogate markers for HIV-1 disease progression. PloS One. 2014;9(12):e114111.
   Google Scholar
• Sanders EJ, Price MA, Karita E, et al. Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa. Aids. 2017;31(18):2541–2546.
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Jama. 2010;304(3):321–333.
   Google Scholar
• Abreu CM, Veenhuis RT, Avalos CR, et al. Myeloid and CD4 T cells comprise the latent reservoir in antiretroviral therapy-suppressed SIVmac251-infected macaques. MBio. 2019;10(4). DOI:https://doi.org/10.1128/mBio.01659-19.
   Google Scholar
• De Scheerder MA, Vrancken B, Dellicour S, et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs. Cell Host Microbe. 2019;26(3):347–358.e347.
   Google Scholar
• Delwart E, Magierowska M, Royz M, et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS. 2002;16(2):189–195.
   Google Scholar
• Wang N, Li Y, Han Y, et al. HIV sequence diversity during the early phase of infection is associated with HIV DNA reductions during antiretroviral therapy. J Med Virol. 2017;89(6):982–988.
   Google Scholar
• Kariuki SM, Selhorst P, Ariën KK, et al. The HIV-1 transmission bottleneck. Retrovirology. 2017;14(1):22.
   Google Scholar
• Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7512):74–77.
   Google Scholar
• Luo L, Wang N, Yue Y, et al. The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study. BMC Infect Dis. 2019;19(1):257.
   Google Scholar
• Lee GQ, Reddy K, Einkauf KB, et al. HIV-1 DNA sequence diversity and evolution during acute subtype C infection. Nat Commun. 2019;10(1):2737.
   Google Scholar
• Bruner KM, Murray AJ, Pollack RA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016;22(9):1043–1049.
   Google Scholar
• Coffin JM, Wells DW, Zerbato JM, et al. Clones of infected cells arise early in HIV-infected individuals. JCI Insight. 2019;4:12.
   Google Scholar
• Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.
   Google Scholar
• Martin GE, Gossez M, Williams JP, et al. Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. AIDS. 2017;31(4):477–484.
   Google Scholar
• Gossez M, Martin GE, Pace M, et al. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. Aids. 2019;33(2):185–197.
   Google Scholar
• Colby DJ, Trautmann L, Pinyakorn S, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. 2018;24(7):923–926.
   Google Scholar
• Harris LD, Tabb B, Sodora DL, et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol. 2010;84(15):7886–7891.
   Google Scholar
• Lederman MM, Funderburg NT, Sekaly RP, et al. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83.
   Google Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533.
   Google Scholar
• Sereti I, Krebs SJ, Phanuphak N, et al. Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis. 2017;64(2):124–131.
   Google Scholar
• Hellmuth J, Slike BM, Sacdalan C, et al. Very early ART initiation during acute HIV infection is associated with normalization of cerebrospinal fluid but not plasma markers of immune activation. J Infect Dis. 2019;220:1885–1891.
   Google Scholar
• Doitsh G, Galloway NLKNL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509–514.
   Google Scholar
• Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis. 1999;180(2):320–329.
   Google Scholar
• Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97(7):3382–3387.
   Google Scholar
• Sharma S, Schlusser KE, Torre P, et al. The benefit of immediate compared to deferred ART on CD4+ Cell count recovery in early HIV infection. London, England: AIDS; 2019.
   Google Scholar
• Ndhlovu ZM, Kamya P, Mewalal N, et al. Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point. Immunity. 2015;43(3):591–604.
   Google Scholar
• Ndhlovu ZM, Kazer SW, Nkosi T, et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Sci Transl Med. 2019;11:493.
   Google Scholar
• Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10(12):e1004543.
   Google Scholar
• Estes JD. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol Rev. 2013;254(1):65–77.
   Google Scholar
• Yero A, Farnos O, Rabezanahary H, et al. Differential dynamics of regulatory T-cell and Th17 cell balance in mesenteric lymph nodes and blood following early antiretroviral initiation during acute simian immunodeficiency virus infection. J Virol. 2019;93(19):19.
   Google Scholar
• Hong JJ, Silveira E, Amancha PK, et al. Early initiation of antiretroviral treatment post SIV infection does not resolve lymphoid tissue activation. AIDS. 2017;31(13):1819–1824.
   Google Scholar
• Planchais C, Hocqueloux L, Ibanez C, et al. Early antiretroviral therapy preserves functional follicular helper T and HIV-specific B cells in the gut mucosa of HIV-1-infected individuals. J Immunol. 2018;200(10):3519–3529.
   Google Scholar
• de Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology. Clin Infect Dis. 2016;63(4):555–561.
   Google Scholar
• Manak MM, Jagodzinski LL, Shutt A, et al. Decreased seroreactivity in individuals initiating antiretroviral therapy during acute HIV infection. J Clin Microbiol. 2019;57(10). DOI:https://doi.org/10.1128/JCM.00757-19.
   Google Scholar
• Baker JV, Sharma S, Achhra AC, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial. J Am Heart Assoc. 2017;6(5). DOI:https://doi.org/10.1161/JAHA.116.004987.
   Google Scholar
• Bush KNV, Teel JL, Watts JA, et al. Association of endothelial dysfunction and antiretroviral therapy in early HIV infection. JAMA Network Open. 2019;2(10):e1913615.
   Google Scholar
• Bellan SE, Dushoff J, Galvani AP, et al. Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts. PLoS Med. 2015;12(3):e1001801.
   Google Scholar
• Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S187–199.
   Google Scholar
• Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–2438.
   Google Scholar
• Le Guillou A, Pugliese P, Raffi F, et al. Reaching the second and third joint united nations programme on HIV/AIDS 90- 90-90Targets is accompanied by a dramatic reduction in primary human immunodeficiency virus (HIV) infection and in recent HIV infections in a large french nationwide HIV cohort. Clin Infect Dis. 2019.
   Google Scholar
• Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr. 2013;62(3):317–321.
   Google Scholar
• Torian LV, Xia Q. Achievement and maintenance of viral suppression in persons newly diagnosed with HIV, New York City, 2006-2009: using population surveillance data to measure the treatment part of “test and treat”. J Acquir Immune Defic Syndr. 2013;63(3):379–386.
   Google Scholar
• Eshleman SH, Wilson EA, Zhang XC, et al. Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017;18(3):100–109.
   Google Scholar
• Fernandez C, van Halsema CL. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV AIDS (Auckl). 2019;11:179–192.
   Google Scholar
• Stekler JD, Tapia K, Maenza J, et al. No time to delay! Fiebig stages and referral in acute HIV infection: seattle primary infection program experience. AIDS Res Hum Retroviruses. 2018;34(8):657–666.
   Google Scholar
• Stekler J, Swenson PD, Wood RW, et al. Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. AIDS. 2005;19(12):1323–1325.
   Google Scholar
• Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med. 2011;364(20):1943–1954.
   Google Scholar
• CDC. Detecting and responding to HIV transmission clusters a guide for health departments DRAFT version 2.0. In: National Center for HIV/AIDS VH, STD, and TB Prevention, Division of HIV/AIDS Prevention, editor. CDC; 2018.
   Google Scholar
• Kasaie P, Radford M, Kapoor S, et al. Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain. PloS One. 2018;13(11):e0206755.
   Google Scholar
• Kuznik A, Iliyasu G, Habib AG, et al. Initiation of antiretroviral therapy based on the 2015 WHO guidelines. AIDS. 2016;30(18):2865–2873.
   Google Scholar
• Vermeersch S, Callens S, De Wit S, et al. Health and budget impact of combined HIV prevention - first results of the BELHIVPREV model. Acta Clin Belg. 2018;73(1):54–67.
   Google Scholar
• Hutter G, Nowak D, Mossner M, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–698.
   Google Scholar
• Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244–248.
   Google Scholar
• Ndung’u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. Nature. 2019;576(7787):397–405.
   Google Scholar
• Kuhlmann AS, Peterson CW, Kiem HP. Chimeric antigen receptor T-cell approaches to HIV cure. Curr Opin HIV AIDS. 2018;13(5):446–453.
   Google Scholar
• Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science (New York, NY). 2014;345(6193):169–174.
   Google Scholar
• Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–228.
   Google Scholar
• Abner E, Jordan A. HIV “shock and kill” therapy: in need of revision. Antiviral Res. 2019;166:19–34.
   Google Scholar
• Mylvaganam GH, Silvestri G, Amara RR. HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol. 2015;35:1–8.
   Google Scholar